Navigation Links
David M. Stout Joins NanoBio Corporation's Board of Directors
Date:5/29/2008

ANN ARBOR, Mich., May 29 /PRNewswire/ -- NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the appointment of David M. Stout to its Board of Directors. Mr. Stout most recently served as President of Pharmaceutical Operations for GlaxoSmithKline Pharmaceuticals.

"We are pleased to welcome David to our Board of Directors and look forward to benefiting from his guidance and contributions," said James R. Baker Jr., M.D., chairman of NanoBio Corporation. "David's 30-plus years of experience in all facets of the pharmaceutical industry -- including his recent experience as head of global pharmaceutical operations for GSK, a world leader in infectious diseases -- will be invaluable to NanoBio as we approach the commercialization of our lead anti-infective and vaccine product candidates."

NanoBio's lead products are topical lotions and mucosal vaccines to combat a wide array of viruses, bacteria and fungi. They include topical treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and bacterial skin infections (including MRSA), as well as mucosal vaccines for seasonal and pandemic influenza, hepatitis B and RSV. The company's nanoemulsion-based products have demonstrated potent antimicrobial effects in several clinical trials, without safety concerns or systemic absorption. The products use a physical mode of action rather than chemical synthesis to disrupt pathogen membranes, rendering the emergence of drug resistance unlikely.

"The platform technology upon which NanoBio's products are based represents a truly novel approach to combating infections and provides a rich pipeline of anti-infective products and vaccines for the future," Stout said. "Given the company's recent and very compelling clinical results, I am particularly excited to be joining the company's board at this time. I look forward to working with NanoBio's management in bringing these new therapies and vaccines to the market."

In his most recent position as President of Pharmaceutical Operations at GSK, Mr. Stout led all global commercial activities, global manufacturing and all vaccine-related activities, including research and development, as well as other executive functions. Additionally, Mr. Stout directed the corporate pandemic flu preparedness program, an international effort that supports governments, health authorities and company employees around the world in planning to respond to a global influenza pandemic. Prior to his tenure at GSK, Mr. Stout held executive leadership positions at Glaxo Wellcome, SmithKline Beecham and Schering-Plough Corporation.

About NanoBio

NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
5. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Immunosyn Corporation Names G. David Criner as CFO
8. Pasteuria Bioscience Taps New CEO David N. Duncan
9. David Mott Appointed Non Executive Director at Shire
10. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
11. Transgenomic Appoints David Pauluzzi to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... While art ... are much more closely connected than one might think. A Mesh Is Also ... open at the University City Science Center’s Esther Klein Gallery (EKG) on August 17 ...
(Date:8/16/2017)... , Aug. 16, 2017  This year,s edition of the Inc. ... in life sciences workforce solutions, has made the list for the third ... recognizes the nation,s fastest-growing private companies based on a set of quantitative ... which includes the fastest-growing companies in the Bay State ... Inc. 5000 ...
(Date:8/15/2017)... , ... August 15, 2017 , ... Kapstone Medical ... 10 years of successes helping medical technology companies and inventors develop and safeguard their ... renowned full-service national engineering firm with a portfolio of clients in the United States ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... Any expert ... that has compromised these disciplines for more than half a century. Despite their ... counted. It is widely known that molecular tags developed for this purpose also ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):